569 related articles for article (PubMed ID: 28898514)
1. Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study.
Yuan Z; DeFalco FJ; Ryan PB; Schuemie MJ; Stang PE; Berlin JA; Desai M; Rosenthal N
Diabetes Obes Metab; 2018 Mar; 20(3):582-589. PubMed ID: 28898514
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D).
Ryan PB; Buse JB; Schuemie MJ; DeFalco F; Yuan Z; Stang PE; Berlin JA; Rosenthal N
Diabetes Obes Metab; 2018 Nov; 20(11):2585-2597. PubMed ID: 29938883
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers.
Yang JY; Wang T; Pate V; Gower EW; Crowley MJ; Buse JB; Stürmer T
Diabetes Obes Metab; 2019 May; 21(5):1223-1236. PubMed ID: 30697897
[TBL] [Abstract][Full Text] [Related]
4. Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study.
Yu OHY; Dell'Aniello S; Shah BR; Brunetti VC; Daigle JM; Fralick M; Douros A; Hu N; Alessi-Severini S; Fisher A; Bugden SC; Ronksley PE; Filion KB; Ernst P; Lix LM;
Diabetes Care; 2020 Oct; 43(10):2444-2452. PubMed ID: 32759360
[TBL] [Abstract][Full Text] [Related]
5. Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: A propensity-matched cohort study.
Adimadhyam S; Lee TA; Calip GS; Smith Marsh DE; Layden BT; Schumock GT
Diabetes Obes Metab; 2018 Dec; 20(12):2792-2799. PubMed ID: 29971914
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
Udell JA; Yuan Z; Rush T; Sicignano NM; Galitz M; Rosenthal N
Circulation; 2018 Apr; 137(14):1450-1459. PubMed ID: 29133607
[TBL] [Abstract][Full Text] [Related]
8. Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes.
Chang HY; Singh S; Mansour O; Baksh S; Alexander GC
JAMA Intern Med; 2018 Sep; 178(9):1190-1198. PubMed ID: 30105373
[TBL] [Abstract][Full Text] [Related]
9. Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis.
Buysman EK; Chow W; Henk HJ; Rupnow MF
BMC Endocr Disord; 2015 Nov; 15():67. PubMed ID: 26527413
[TBL] [Abstract][Full Text] [Related]
10. Real-world comparison of hospitalization costs for heart failure in type 2 diabetes mellitus patients with established cardiovascular disease treated with canagliflozin versus other antihyperglycemic agents.
Chen YW; Voelker J; Tunceli O; Pericone CD; Bookhart B; Durkin M
J Med Econ; 2020 Apr; 23(4):401-406. PubMed ID: 31801393
[No Abstract] [Full Text] [Related]
11. Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study.
Yuan Z; DeFalco F; Wang L; Hester L; Weaver J; Swerdel JN; Freedman A; Ryan P; Schuemie M; Qiu R; Yee J; Meininger G; Berlin JA; Rosenthal N
Curr Med Res Opin; 2020 Jul; 36(7):1117-1124. PubMed ID: 32338068
[No Abstract] [Full Text] [Related]
12. Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program.
Matthews DR; Wysham C; Davies M; Slee A; Alba M; Lee M; Perkovic V; Mahaffey KW; Neal B
Diabetes Obes Metab; 2020 Nov; 22(11):2199-2203. PubMed ID: 32691499
[TBL] [Abstract][Full Text] [Related]
13. Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview.
Davidson JA; Sloan L
Adv Ther; 2017 Jan; 34(1):41-59. PubMed ID: 27854055
[TBL] [Abstract][Full Text] [Related]
14. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.
Wang L; Voss EA; Weaver J; Hester L; Yuan Z; DeFalco F; Schuemie MJ; Ryan PB; Sun D; Freedman A; Alba M; Lind J; Meininger G; Berlin JA; Rosenthal N
Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1620-1628. PubMed ID: 31456304
[TBL] [Abstract][Full Text] [Related]
15. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
Rahelić D; Javor E; Lucijanić T; Skelin M
Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
[TBL] [Abstract][Full Text] [Related]
16. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk of Amputation: What Is Currently Known?
Misher A; Ampuero A; Phan R; Aziz S; Ebong E; Braich J; Dyches K; Southwood R
Am J Ther; 2020 Mar; 28(1):e96-e110. PubMed ID: 32384319
[TBL] [Abstract][Full Text] [Related]
17. Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use.
Potier L; Roussel R; Velho G; Saulnier PJ; Bumbu A; Matar O; Schneider F; Ragot S; Marre M; Mohammedi K; Hadjadj S
Diabetologia; 2019 Jun; 62(6):939-947. PubMed ID: 30809716
[TBL] [Abstract][Full Text] [Related]
18. Use of Sodium-Glucose Co-Transporter-2-Inhibitors (SGLT2-Is) and Risk of Lower Limb Amputation.
Werkman NCC; Nielen JTH; van den Bergh JPW; Ejskjaer N; Røikjer J; Schaper NC; Rossi B; Klungel O; Vestergaard P; de Vries F; Driessen JHM
Curr Drug Saf; 2021; 16(1):62-72. PubMed ID: 32767909
[TBL] [Abstract][Full Text] [Related]
19. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.
Ueda P; Svanström H; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Pasternak B
BMJ; 2018 Nov; 363():k4365. PubMed ID: 30429124
[TBL] [Abstract][Full Text] [Related]
20. Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents.
Wang Y; Desai M; Ryan PB; DeFalco FJ; Schuemie MJ; Stang PE; Berlin JA; Yuan Z
Diabetes Res Clin Pract; 2017 Jun; 128():83-90. PubMed ID: 28448895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
